Neutralizing antibodies prevent the binding of the S1-RBD spike protein of COVID19 to the ACE2 receptor in the respiratory mucous membrane, the path through which the COVID-19 virus penetrates the human body. This evidence concerns the gene PSMD1 and COVID-19.